Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1B, Single Center, Randomized, Open Label, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single NGM313 Dose or Daily Oral Pioglitazone in Obese Participants With Insulin Resistance and Increased Liver Fat

Trial Profile

A Phase 1B, Single Center, Randomized, Open Label, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single NGM313 Dose or Daily Oral Pioglitazone in Obese Participants With Insulin Resistance and Increased Liver Fat

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs NGM 313 (Primary) ; Pioglitazone
  • Indications Obesity
  • Focus Pharmacodynamics; Proof of concept
  • Sponsors NGM Biopharmaceuticals
  • Most Recent Events

    • 03 Jan 2019 According to a Merck & Co media release, Merck has exercised its option to license NGM313 (MK-3655) which was triggered completion of this study.
    • 03 Jan 2019 Status changed from recruiting to completed, as reported in a Merck & Co media release.
    • 12 Nov 2018 According to a a NGM Biopharmaceuticals media release, data will be presented today during a late breaker poster session at AASLD's The Liver Meeting 2018 in San Francisco.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top